Compounds / HGH Fragment 176-191

HGH Fragment 176-191

Also known as: HGH Frag 176-191, Growth Hormone Fragment

No human data Not FDA-approved Category: GLP-1 and Metabolic

The compounds described in this library are research-use-labeled chemicals and are not FDA-approved for human use. This content is factual scientific reference drawn from published literature. It is not medical, dosing, or purchasing advice. VialReport does not sell, supply, or distribute any compound.

Short summary

A fragment of human growth hormone corresponding to residues 176 to 191, closely related to AOD-9604 and marketed on similar lipolytic rationale. No human clinical evidence for the fragment as sold.

Dive deeper

Origin and Development

Derived from the same line of research as AOD-9604: the observation that the C-terminal region of human growth hormone carries lipolytic activity distinct from the hormone's growth-promoting effects.

Mechanism as Understood in the Literature

Described in preclinical work as influencing fat metabolism through effects on lipolysis and lipogenesis. As with AOD-9604, the receptor mechanism is not well characterized.

Research Status

Preclinical. Animal studies have examined effects on fat metabolism. There is no meaningful human clinical evidence for this fragment, and the closely related AOD-9604 failed to demonstrate efficacy in human obesity trials, which is relevant context.

Regulatory status

Not FDA-approved for any indication. Prohibited in competitive sport under World Anti-Doping Agency rules.

Commonly Confused With

Frequently conflated with AOD-9604. The two are closely related fragments of the same region of growth hormone but are not identical molecules, and the naming is used loosely across the market. A vial labeled one may contain the other.

How This Compound Is Marketed

Vendor marketing for this compound typically references fat loss. VialReport does not evaluate or endorse these claims. See Research Status above for what the published literature actually establishes.

Analytical Profile

The native 16-residue C-terminal fragment of human growth hormone, without the N-terminal tyrosine that defines AOD-9604. Because that single residue is the only difference, the mass gap between the two is small and intact mass alone will not reliably distinguish them. Confident differentiation requires an exact sequence on the target specification, a defined disulfide state, a correct free-base or salt-form reference standard, and ideally fragmentation or sequence-confirming mass spectrometry where substitution is a concern.

Stability and Handling

Supplied lyophilized. Stable lyophilized at reduced temperature, less stable reconstituted.

Key Literature

  1. 01 Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. [Note: this study concerns AOD-9604, a related but chemically distinct compound. Included as related-compound context, not as direct evidence for HGH Fragment 176-191.]

VialReport publishes factual reference information and independent test data. Nothing here is medical, dosing, or purchasing advice.

Published reports

Reports for HGH Fragment 176-191

No reports for this compound yet.

Want a vendor’s version of this compound tested? Request it and we’ll notify you when a report publishes.

Request a test

Stay current

Get notified when new reports publish.

No membership required. We email findings when they're published. Not updates, not promotions, just reports.

Powered by MailerLite. No spam. Unsubscribe anytime.